triple negative breast cancer

[Acta Pharmacologica Sinica] WZ-2-033 significantly inhibited the proliferation, colony survival, migration, and invasion of TNBC cells and gastric cancer cells with aberrant signal transducer and activator of transcription 3 (STAT3) activation.

[CytoDyn, Inc.] CytoDyn, Inc., a biotechnology company developing leronlimab, a CCR5 antagonist, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic TNBC has advanced from Phase Ib to a Phase II trial.

[Communications Biology] Researchers showed that a combination immunotherapy platform utilizing low dose chemotherapy combined with oncolytic virotherapy increased tumor-infiltrating lymphocytes, in otherwise immune-bare tumors, allowing 60% of mice to achieve durable tumor regression when treated with immune checkpoint blockade.

[Nature Communications] Scientists reported that cells derived from claudin-low mammary tumors, a mesenchymal subtype of triple-negative breast cancer, exhibited a distinctive organoid structure with extended “spikes” in 3D matrices.

[Communications Biology] Investigators demonstrated that profiling functional proteins involved in cell-to-cell interactions in the microenvironment could predict recurrence and overall survival.

[Signal Transduction and Targeted Therapy] The authors reported a novel function of factor Kinectin 1 (KTN1) as a carcinogenic promoter in TNBC. KTN1 expression in TNBC was increased compared with adjacent tissues or luminal or Her2 subtypes of breast cancer, and TNBC patients with high KTN1 expression had poor prognosis.